Werewolf Therapeutics investor holds 5.2% stake

Werewolf Therapeutics, Inc. (HOWL) reports that German private investor Peter Moll has filed a Schedule 13G disclosing a passive stake in the company’s common stock.

Rhea-AI Filing Summary

Werewolf Therapeutics, Inc. (HOWL) reports that German private investor Peter Moll has filed a Schedule 13G disclosing a passive stake in the company’s common stock.

Moll beneficially owns 2,537,138 shares of Werewolf Therapeutics common stock, representing 5.2% of the outstanding class. He reports sole voting and sole dispositive power over all of these shares, with no shared voting or dispositive power. The filing describes him as a private investor and German citizen.

Key Figures

Shares beneficially owned: 2,537,138 shares Percent of class: 5.2% Sole Voting Power: 2,537,138 shares +2 more

5 metrics

Shares beneficially owned 2,537,138 shares Common stock of Werewolf Therapeutics, Inc. reported on Schedule 13G

Percent of class 5.2% Portion of Werewolf Therapeutics common stock class beneficially owned by Peter Moll

Sole Voting Power 2,537,138 shares Shares over which Peter Moll has sole power to vote or direct the vote

Sole Dispositive Power 2,537,138 shares Shares over which Peter Moll has sole power to dispose or direct disposition

Par value of common stock $0.0001 per share Title of class of securities of Werewolf Therapeutics, Inc.

Key Terms

beneficially owned, Sole Voting Power, Sole Dispositive Power, Percent of class, +1 more

5 terms

beneficially owned financial

"Amount beneficially owned: 2537138"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole Voting Power financial

"Sole Voting Power 2,537,138.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Sole Dispositive Power financial

"Sole Dispositive Power 2,537,138.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Percent of class financial

"Percent of class: 5.2 %"

Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

Schedule 13G regulatory

"Moll has filed a Schedule 13G disclosing a passive stake"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What percentage of Werewolf Therapeutics (HOWL) does Peter Moll report owning?

Peter Moll reports beneficial ownership of 5.2% of Werewolf Therapeutics’ common stock on Schedule 13G, based on his disclosed shareholdings in the company.

How many Werewolf Therapeutics (HOWL) shares does Peter Moll beneficially own?

Peter Moll beneficially owns 2,537,138 shares of Werewolf Therapeutics, Inc. common stock, according to the Schedule 13G filing.

Does Peter Moll have sole or shared voting power over his HOWL shares?

Peter Moll reports sole voting power over 2,537,138 shares of Werewolf Therapeutics common stock and no shared voting power over any shares.

What dispositive power does Peter Moll report over his Werewolf Therapeutics (HOWL) shares?

The Schedule 13G states that Peter Moll has sole dispositive power over 2,537,138 shares of Werewolf Therapeutics common stock and no shared dispositive power.

What is the reporting status and role of Peter Moll in relation to HOWL?

Peter Moll files as a private investor and reports beneficial ownership of Werewolf Therapeutics common stock on Schedule 13G, indicating a passive 5.2% stake rather than an activist or controlling position.

What is Peter Moll’s citizenship and address as disclosed for his HOWL holdings?

Peter Moll is disclosed as German, with an address in Dresden, Germany, in connection with his reported ownership of Werewolf Therapeutics common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/21/2026 - 11:12 AM Accepted by SEC EDGAR 09/21/2026 - 11:11 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Werewolf Therapeutics, Inc.

(Name of Issuer)

Common stock 0,0001$ per share

(Title of Class of Securities)

95075A107

(CUSIP Number)

09/18/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 95075A107

1

Names of Reporting Persons

MOLL PETER

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

GERMANY

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,537,138.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,537,138.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,537,138.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.2 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Private Investor

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Werewolf Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 303 WYMAN STREET, SUITE 300, WALTHAM, MASSACHUSETTS, 02451
Item 2.
(a)	Name of person filing: Peter Moll
(b)	Address or principal business office or, if none, residence: Degelestr. 3, 01324 Dresden, Germany
(c)	Citizenship: German
(d)	Title of class of securities: Common stock 0,0001$ per share
(e)	CUSIP Number(s): 95075A107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 2537138
(b)	Percent of class: 5.2 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 2537138
	(ii) Shared power to vote or to direct the vote: 5.2
	(iii) Sole power to dispose or to direct the disposition of: 2537138
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

MOLL PETER

Signature:	PeterMoll
Name/Title:	Owner
Date:	09/21/2026

Comments accompanying signature: Peter Moll